Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Andrew McConaghie

Senior Writer

London, UK

Andrew writes on a range of topics across biopharma sector R&D and commercial issues, from new biotech start-ups to COVID-19 vaccines and new cancer, cell and gene therapies.

Latest From Andrew McConaghie

Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage

Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.

ASCO Clinical Trials

Pfizer Will Struggle To Catch Novo Nordisk With Oral Obesity Treatments

Novo Nordisk reasserted its dominance in the GLP-1 agonist field this week, while Pfizer must hope that one of its two shots on goal is a success.

Research & Development Strategy

Novo Nordisk’s Obesity Drug Activities Break UK Rules Again

The company has been found in breach of the UK code once again for its work with pharmacists,  although this time Novo Nordisk has escaped the heaviest censure.

Companies Commercial

Arrowhead’s RNAi Gaining Momentum In Heart And Lung Targets

Arrowhead has spent years in the shadows of rivals Alnylam and Ionis, but could make its mark with new ways to target cardiovascular and lung disease using RNA interference.

Companies Clinical Trials

Novo Nordisk’s Obesity Drug Activities Break UK Rules Again

The company has been found in breach of the UK code once again for its work with pharmacists,  although this time Novo Nordisk has escaped the heaviest censure.

Companies Commercial

Cystinosis Results Help Rebuild Confidence In AvroBio’s Gene Therapy

The lentiviral gene therapy company is still trading below cash, but the cystinosis results add extra momentum to its comeback.

Metabolic Disorders Commercial
See All
UsernamePublicRestriction

Register